The Business Cocktail Archives | DelveInsight Business Research Skip to main content
delveinsight blog
  • ABOUT
    • About Us
    • Our Leadership
    • Our Clients
  • CAPABILITIES & SOLUTIONS
    • Reports
    • Competitive Intelligence
    • Case Study
  • CONSULTING SERVICE
  • REPORT STORE
  • MEDIA
    • Blog
    • Press Releases
    • White Papers / Newsletter
    • Events
  • CAREER
  • CONTACT US
  • Report Store

Category: The Business Cocktail

Dec 3 Cumberland’s methotrexate product gets approval  in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter

Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter

Dec 3, 2019Dec 3, 2019 DelveInsight Leave a comment

Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. Cumberland pharmaceuticals pharma company focusing on…

Read More
Nov 28 Sanofi’s Toujeo Okayed to treat Type 1,2 Diabetes; Hope for Alzheimer’s patients as TauRx shows positive results; Pfizer, Novartis along with others invest USD 2 Billion in Gene therapy

Sanofi’s Toujeo Okayed to treat Type 1,2 Diabetes; Hope for Alzheimer’s patients as TauRx shows positive results; Pfizer, Novartis along with others invest USD 2 Billion in Gene therapy

Nov 28, 2019Dec 5, 2019 DelveInsight Leave a comment

Sanofi’s Toujeo has received FDA recommendation for its expanded use in both Type 1 and Type 2 Diabetes. Toujeo is an insulin glargine injection to control…

Read More
Nov 26 Novartis buys Medicines Co. for USD 9.7 Billion; Alexion’s SOLIRIS receives approval in Japan for NMOSD; Ferring and Blackstone teams up to advance Bladder cancer gene therapy

Novartis buys Medicines Co. for USD 9.7 Billion; Alexion’s SOLIRIS receives approval in Japan for NMOSD; Ferring and Blackstone teams up to advance Bladder cancer gene therapy

Nov 26, 2019Nov 26, 2019 DelveInsight Leave a comment

Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market….

Read More
Nov 21 GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion

GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion

Nov 21, 2019Nov 21, 2019 DelveInsight Leave a comment

Global Healthcare Opportunities (GHO) Capital, a London-based healthcare investment firm, has recently netted USD 1.1 Billion to advance European healthcare. The company plans to use the…

Read More
Nov 19 Nordisk ties up with Dicerna;  Pfizer’s drug gets FDA nod; Alkermes buys Rodin

Nordisk ties up with Dicerna; Pfizer’s drug gets FDA nod; Alkermes buys Rodin

Nov 19, 2019Nov 19, 2019 DelveInsight Leave a comment

Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to…

Read More
Nov 14 Merck buys Calporta’s preclinical neurodegenerative assets; GSK’s Nucala targets rare inflammatory disease; AbbVie Sells bonds to Fund Allergan takeover

Merck buys Calporta’s preclinical neurodegenerative assets; GSK’s Nucala targets rare inflammatory disease; AbbVie Sells bonds to Fund Allergan takeover

Nov 14, 2019Nov 14, 2019 DelveInsight Leave a comment

AbbVie has traded off its bonds worth USD 30 Billion to finance the purchase of the Allergan.   AbbVie this year in June has agreed to…

Read More
Nov 12 FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit; FDA approves first therapy to treat a rare blood disorder

FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit; FDA approves first therapy to treat a rare blood disorder

Nov 12, 2019Nov 12, 2019 DelveInsight Leave a comment

The US FDA for the third time has refused to give approval to Lipocine’s oral testosterone drug, Tlando. The drug is an oral testosterone replacement therapy…

Read More
Nov 7 Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences

Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences

Nov 7, 2019Nov 7, 2019 DelveInsight Leave a comment

Switzerland-based Vifor Pharma and Germany-based Evotech AG have collaborated for the development and discovery of new treatments for kidney diseases. The launch of a new 50:50…

Read More
Nov 5 AstraZeneca tops the first Pharma Invention Index; Amgen to buy 20.5% stake in a Chinese pharmaceutical, BeiGene; Ascentage, Henlius collaborates to develop a Combination therapy

AstraZeneca tops the first Pharma Invention Index; Amgen to buy 20.5% stake in a Chinese pharmaceutical, BeiGene; Ascentage, Henlius collaborates to develop a Combination therapy

Nov 5, 2019Nov 5, 2019 DelveInsight Leave a comment

Amgen has announced to purchase 20.5% of the stake in Chinese-American drug company BeiGene. As per the deal signed, Amgen will develop and commercialize around two…

Read More
Oct 31 AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood

AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood

Oct 31, 2019Oct 31, 2019 DelveInsight Leave a comment

AstraZeneca has announced the licensing-out of two of its drugs Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. According to the deal…

Read More

Posts navigation

1 2 … 14 Older posts

Recent Posts

  • Are Rare diseases truly Rare?
  • Hype over Gene Therapy: Challenges and Opportunities
  • Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
  • The Regulatory process for drug approval in the MENA region
  • Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter

Browse by Category

  • Anti-coagulants (8)
  • API Business Opportunity (5)
  • Articles (284)
  • Atrial Fibrillation (6)
  • Business Consultant (445)
    • Pharma Consultant (426)
  • Chimeric Antigen Receptor (CAR) T-cell Therapy (7)
  • CNS Indications (1)
  • CVS Indications (4)
  • DelveInsight's Drug Report (153)
  • DelveInsight's Indication Pipeline Reports (68)
  • DelveInsight's Oncology based Reports (45)
  • Gene Therapy Products (31)
  • Infographics (40)
  • new therapeutic target (5)
  • Newsletter (2)
  • Notizia (154)
  • Oncology based Indications (11)
  • Orphan market (4)
  • PD-1 and PD-L1 inhibitors (5)
  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (1)
  • Pulmonary arterial hypertension (1)
  • Rising of Orphan Drug Development (3)
  • Snippets (127)
  • Specialized Reports (15)
  • The Business Cocktail (138)
  • Uncategorized (61)
  • Venous Thromboembolism (3)

Archives

  • December 2019 (8)
  • November 2019 (24)
  • October 2019 (27)
  • September 2019 (23)
  • August 2019 (22)
  • July 2019 (25)
  • June 2019 (30)
  • May 2019 (29)
  • April 2019 (29)
  • March 2019 (27)
  • February 2019 (20)
  • January 2019 (18)
  • December 2018 (19)
  • November 2018 (26)
  • October 2018 (21)
  • September 2018 (20)
  • August 2018 (26)
  • July 2018 (13)
  • June 2018 (5)
  • May 2018 (8)
  • April 2018 (6)
  • March 2018 (14)
  • February 2018 (11)
  • January 2018 (15)
  • December 2017 (8)
  • November 2017 (13)
  • October 2017 (8)
  • September 2017 (14)
  • August 2017 (13)
  • July 2017 (9)
  • June 2017 (14)
  • May 2017 (20)
  • April 2017 (19)
  • March 2017 (24)
  • February 2017 (21)
  • January 2017 (23)
  • December 2016 (22)
  • November 2016 (23)
  • October 2016 (17)
  • September 2016 (21)
  • August 2016 (17)
  • May 2016 (4)
  • March 2016 (8)
  • February 2016 (3)
  • January 2016 (7)
  • November 2015 (1)
  • October 2015 (1)
  • September 2015 (2)
  • August 2015 (2)
  • July 2015 (8)
  • June 2015 (4)
  • May 2015 (1)
  • April 2015 (5)
  • March 2015 (6)
  • February 2015 (2)
  • January 2015 (5)
  • December 2014 (17)
  • November 2014 (2)
  • September 2014 (1)
  • August 2014 (7)
  • July 2014 (7)
delveinsight


Quick Links

  • About
  • Capabilities & Solutions
  • Report Store
  • Media
  • Career
  • Contact Us

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Tweets by @DelveInsight

Copyright © 2019 Delveinsight.

  • Sitemap
  • Terms & Conditions
  • Privacy policy